Emergent BioSolutions related Press Releases
Emergent BioSolutions Announces Commencement of Phase I/II Trial of Anthrax Immune Globulin for Treating Anthrax Disease
Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease ROCKVILLE, Md., Mar 17, 2009 (BUSINESS WIRE) ----Emergent
... Read more...Emergent BioSolutions Ends $78 Million Deal to Acquire Protein Sciences
Emergent BioSolutions Ends $78 Million Deal to Acquire Protein Sciences January 2, 2009 ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS - News) announced today that it has
... Read more...U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax® and Anthrax Immune Globulin under Prep Act
U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax® and Anthrax Immune Globulin under Prep Act HHS Secretary Determines That Potential Threat of Exposure to Anthrax... Read more...
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Gen
Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine --AV7909 Contract is in Addition to Recently... Read more...
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continu
Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody ROCKVILLE,... Read more...
PRESS RELEASE: HHS Remains Committed to Procurement of BioThrax Under Current Contract
U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax Under Current Contract ROCKVILLE, Md. -- Nov. 19, 2007--Emergent BioSolutions Inc. (NYSE:EBS) announced... Read more...
PRESS RELEASE: Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services
Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions, announced today that it has signed a three year contract with the... Read more...
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




